0000914475-24-000051.txt : 20240208
0000914475-24-000051.hdr.sgml : 20240208
20240208194647
ACCESSION NUMBER: 0000914475-24-000051
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240206
FILED AS OF DATE: 20240208
DATE AS OF CHANGE: 20240208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Boyer David W.
CENTRAL INDEX KEY: 0001909817
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 24610826
MAIL ADDRESS:
STREET 1: C/O NEUROCRINE BIOSCIENCES, INC.
STREET 2: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
wk-form4_1707439596.xml
FORM 4
X0508
4
2024-02-06
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001909817
Boyer David W.
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Corp. Affairs Officer
1
Common Stock
2024-02-06
4
S
0
240
141.96
D
5110
D
Common Stock
2024-02-06
4
S
0
216
141.96
D
4894
D
Common Stock
2024-02-08
4
S
0
700
134.189
D
5523
D
Common Stock
2024-02-08
4
S
0
628
136.78
D
4895
D
Sale of 240 shares of common stock issued upon vesting of 456 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (216) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Sale of 700 shares of common stock issued upon vesting of 1,329 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (629) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
/s/ Darin Lippoldt, Attorney-in-Fact
2024-02-08